首页> 外文会议>World biomaterials congress >Polydimethylsiloxane/calcium phosphate nanoparticles developed by biomimetic technique to produce tracheobronchial stents
【24h】

Polydimethylsiloxane/calcium phosphate nanoparticles developed by biomimetic technique to produce tracheobronchial stents

机译:通过仿生技术开发的聚二甲基硅氧烷/磷酸钙纳米粒子可生产气管支气管支架

获取原文

摘要

Introduction: Properties of polydimethylsiloxane (PDMS) promise a great convenience in clinical applications because of the good mechanical and chemical characteristics. In general, bioceramics exhibit excellent biological performance that can promote new bone formation to produce a pore-like structure. Hydroxyapatite (HA) is similar to primary constituent of bone. HA may form a bond with bone tissues and it possesses excellent biocompatlbility. However, HA is brittle. So it is interesting to combine the advantages of HA and PDMS and to form a new material system. An important use of the PDMS has been to develop stents, especially for tracheobronchial applications. One approach to improving the bioactivity in this case is a mixture of biologically active PDMS and nanosized-HA (n-HA). A new method was developed in order to produce stents with PDMS incorporated with bioactive inorganic substances. In this process the formation of CP nanoparticles occurs in situ facilitating the production and incorporation of CP. Materials and Methods: To produce PDMS/CP composite, Ca(OH)2 was mixed to PDMS in an open two-roll mixer. Suitable quantity of H3PO4 was added and homogenized. Biomaterial was pressed in metallic molds to obtain samples and cross-linked at 185 oC for 45 min. Phase composition was analyzed by XRD under 40 kV and 40 mA. TEM was performed to observe the nanoparticles of the material. In vitro tests were carried out dipped samples in SBF to simulate the behavior of the material into the human body. Shore A hardness was measured according to ASTM D2240 in five samples. Results and Discussion: The method to produce PDMS/CP consists in obtain the CP in situ during the production of PDMS composite. According to literature, dibasic calcium phosphate dihydrate (DCPD) can transform in dibasic calcium phosphate anhydrate (DCPA) at temperatures around 80oC, Therefore, after cross-linking reaction, DCPD suffered dehydration to form DCPA. XRD presents DCPA and HA as filler phases in the composite. The pH measurement is around 7.12, that is recommended range for implantable materials. Shore A is 30.50 ± 0.75 for PDMS and is 42.00 ± 0.52 for PDMS/CP. The higher hardness of composite occurs due to presence of filler phases (HA and DCPA). TEM analysis shows presence of spherical nanoparticles of CP with dimensions around 20 nm homogeneously distributed. Conclusion: Composite produced by biomimetic method shown HA and DCPA after cross-linked. Shore A shown higher values for PDMS/CP, because of the presence of filler phases. Composite presented CP nanoparticles homogenously distributed. The pH found is recommended range to implantation of the biomaterial.
机译:简介:由于良好的机械和化学特性,聚二甲基硅氧烷(PDMS)的性能有望在临床应用中带来极大的便利。通常,生物陶瓷表现出优异的生物学性能,可以促进新的骨形成以产生毛孔状结构。羟基磷灰石(HA)与骨骼的主要成分相似。 HA可以与骨骼组织形成键,并且具有出色的生物相容性。但是,HA很脆弱。因此,将HA和PDMS的优点相结合并形成一个新的材料系统是很有趣的。 PDMS的重要用途是开发支架,尤其是用于气管支气管的支架。在这种情况下,一种提高生物活性的方法是生物活性PDMS和纳米级HA(n-HA)的混合物。为了生产带有结合了生物活性无机物质的PDMS的支架,开发了一种新方法。在此过程中,CP纳米颗粒的形成就地发生,从而促进了CP的生产和掺入。材料和方法:为了生产PDMS / CP复合材料,在开放式两辊混合器中将Ca(OH)2与PDMS混合。加入适量的H 3 PO 4并均质化。将生物材料压入金属模具中以获得样品,并在185 oC交联45分钟。在40 kV和40 mA下通过XRD分析相组成。进行TEM以观察材料的纳米颗粒。在SBF中浸渍样品进行了体外测试,以模拟该材料进入人体的行为。肖氏A硬度根据ASTM D2240在五个样品中测量。结果与讨论:制备PDMS / CP的方法包括在PDMS复合材料的生产过程中原位获得CP。根据文献,磷酸氢二钙二水合物(DCPD)可以在约80oC的温度下转化为磷酸氢二钙无水物(DCPA),因此,交联反应后,DCPD脱水形成DCPA。 XRD将DCPA和HA表示为复合物中的填料相。 pH测量值约为7.12,这是可植入材料的推荐范围。对于PDMS,邵氏A为30.50±0.75;对于PDMS / CP,肖氏A为42.00±0.52。复合材料的较高硬度是由于存在填料相(HA和DCPA)而产生的。 TEM分析显示,CP球形纳米颗粒的存在均匀分布在20 nm左右。结论:仿生法生产的复合材料交联后具有HA和DCPA。由于存在填充相,肖氏A的PDMS / CP值较高。复合材料呈现出均匀分布的CP纳米颗粒。推荐的pH范围是植入生物材料的推荐范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号